Evidence map›Paper›PMID 28444148›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017

Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES.

Adeel A Butt, Peng Yan, Kara W Chew, Judith Currier, Kathleen Corey, Raymond T Chung, Ashfaq Shuaib, Abdul-Badi Abou-Samra, Javed Butler, Matthew S Freiberg

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Hepatitis C Virus Structure: Defined by What It Is Not.Cold Spring Harbor perspectives in medicine · 2020
    Review
  17. The impact of infection with hepatitis C virus on cardiovascular risk.American journal of cardiovascular disease · 2020
    Review
  18. Metabolic Syndrome in HIV/HCV Co-infected Patients.Current treatment options in infectious diseases · 2019
    Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Adeel A ButtVA Pittsburgh Healthcare System, Pennsylvania.
Peng YanVA Pittsburgh Healthcare System, Pennsylvania.
Kara W ChewDavid Geffen School of Medicine at University of California, Los Angeles.
Judith CurrierDavid Geffen School of Medicine at University of California, Los Angeles.
Kathleen CoreyMassachusetts General Hospital and Harvard Medical School, Boston.
Raymond T ChungMassachusetts General Hospital and Harvard Medical School, Boston.
Ashfaq ShuaibHamad Healthcare Quality Institute, Hamad Medical Corporation, Doha, Qatar.
Abdul-Badi Abou-SamraHamad Healthcare Quality Institute, Hamad Medical Corporation, Doha, Qatar.
Javed ButlerState University of New York at Stony Brook.
Matthew S FreibergVanderbilt University, Nashville, Tennessee.
Hamad Medical Corporation · QAUniversity of California, Los Angeles · USCornell University · USHarvard University · USMassachusetts General Hospital · USStony Brook University · USVanderbilt University · USVA Pittsburgh Healthcare System · US

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
UCLA Clinical and Translational Science InstituteKL2TR000122 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$4.5M
NCATS NIH HHS KL2 TR000122NCATS NIH HHS KL2 TR001882
6 · The paper itself

Abstract

backgroundRisk of acute myocardial infarction (AMI) among hepatitis C virus (HCV)-positive versus HCV-negative persons with similar lipid levels is unknown. We determined incident AMI rates among HCV-positive and HCV-negative men among various lipid strata.

methodsWe created a propensity score matched (PSM) cohort and a low cardiovascular disease (CVD) risk cohort. Primary outcome was incident AMI rates by HCV status in each lipid strata using National Cholesterol Program guidelines for lipid strata.

resultsWe identified 85863 HCV-positive and HCV-negative men in the PSM population. The incidence rates/1000 patient-years (95% confidence interval [CI]) for AMI among total cholesterol (TC) 200-239 stratum were 5.3 (4.89, 5.71) for HCV-positive versus 4.71 (4.42, 5) for HCV-negative men (P = .02) and for TC >240 mg/dL were 7.38 (6.49, 8.26) versus 6.17 (5.64, 6.71) (P = .02). For low-density lipoprotein cholesterol (LDL) of 130-159 mg/dL, AMI rates were 5.44 (4.97, 5.91) for HCV-positive and 4.81 (4.48, 5.14) for HCV-negative men (P = .03). The rise in risk with increasing lipid levels was greater in younger HCV-positive than in HCV-negative men (e.g., TC > 240 mg/dL: age >50 HR 1.38 [HCV-positive] and 1.12 [HCV-negative]; age ≤50 HR 1.6 [HCV-positive] and 1.29 [HCV-negative]), and more profoundly altered in HCV-positive men by lipid lowering therapy (change in HR with lipid-lowering therapy for TC >240 mg/dL from 1.82 to 1.19 [HCV-positive] from 1.48 to 1.03 [HCV-negative]).

conclusionsHCV-positive men have a higher risk of AMI than HCV-negative men at higher TC/LDL levels; this risk is more pronounced at a younger age. Lipid lowering therapy significantly reduces this risk, with more profound reduction among HCV-positive versus HCV-negative men at similar lipid levels.

Indexed as

Cohort StudiesHepatitis CHumansLipidsMaleMiddle AgedMyocardial InfarctionPropensity ScoreRisk FactorsLipidsacute myocardial infarctioncholesterolERCHIVEShepatitis C viruslipid

Identifiers

PMID28444148
PMCPMC5850566
OpenAlexW2608167701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.